Peptide Academy · Approved peptides · Education only
Octreotide: What FDA Approved, Explained Simply
By BioLabs Research · Peptide Academy › Approved Peptides
Your body has hormones that say 'go' and hormones that say 'stop'. Somatostatin is one of the great 'stop' signals. The problem is that natural somatostatin breaks down within minutes. Octreotide is what chemists built to fix that.
On this page we'll keep it simple: what octreotide is, what it does according to the official FDA label, and exactly what FDA approved. Nothing here is advice on using a medicine. Approved medicines are prescribed by licensed clinicians, and the official label is always the controlling text.
What it is
Octreotide is a short, eight-amino-acid peptide designed to copy the action of somatostatin. It lasts much longer in the body than the natural hormone. Many generic versions are now approved as well, and Drugs@FDA lists several.
What it does
Section 12.1 of the FDA label says octreotide acts much like natural somatostatin, and is an even stronger inhibitor of growth hormone, glucagon and insulin. It also suppresses the release of several gut hormones and messengers, including serotonin, gastrin, VIP (vasoactive intestinal peptide), secretin and motilin. Picture a dimmer switch turned down on several hormone signals at once.
For a deeper dive, see the peer-reviewed review: N Engl J Med 1996 — 'Octreotide' (PubMed 8532003).
What FDA approved
Labelled indication: Acromegaly: to reduce growth hormone and IGF-1 blood levels in patients who had an inadequate response to, or cannot be treated with, surgery, pituitary irradiation and bromocriptine. Metastatic carcinoid tumors: symptomatic treatment of severe diarrhea and flushing. VIPomas: treatment of the profuse watery diarrhea associated with these tumors.
Exact wording and populations differ between approved octreotide products. Each product's own label is the controlling text.
Regulatory status at a glance
| Item | Status | Source |
|---|---|---|
| Application | NDA 019667 | Drugs@FDA |
| Original approval date | October 21, 1988 | openFDA |
| Labelled indication | As quoted above | DailyMed |
| Boxed warning | None | DailyMed |
| 503A bulks list | Not applicable: this is an FDA-approved product | — |
A common misunderstanding
Octreotide shows a key idea in peptide drug design: nature's version isn't always practical, so chemists keep the 'active' part and rebuild the rest for stability.
What FDA approval actually means
Here's the part most people get wrong. FDA approval is narrow. It covers a specific product, from a specific manufacturer, for a specific use, in a specific group of patients, with a specific label. The approval does not belong to the molecule floating around in the world. A chemical with the same name, sold by someone else for any other purpose, is not an approved drug. That's why we quote the label's own indication and nothing more.
How we checked these facts
Every regulatory fact on this page comes from an official U.S. government source: the Drugs@FDA database (and its openFDA API) for the application number and approval date, and the current FDA label on DailyMed for the indication, boxed warning and mechanism. Mechanism background also comes from a peer-reviewed review indexed in PubMed. We don't reproduce usage instructions from labels. This is an education page, not a guide to using any medicine.
Why approved peptides matter for peptide science
Approved peptides prove that peptide research can turn into real medicines. They also show how high the bar is: controlled human trials, manufacturing inspections, a written label, and safety monitoring that continues after approval. Most peptides you read about online never got anywhere near that bar. Chapter 7 of the Academy explains where the line sits.
FAQ
What is acromegaly?
A condition in which the body makes too much growth hormone, usually because of a pituitary tumour.
Is octreotide the same as somatostatin?
No. It is a shorter, longer-lasting analogue that acts on the same receptors.
Is this page medical advice?
No. It is education only. Talk to a licensed healthcare professional about any medicine.
References: Drugs@FDA; openFDA; DailyMed label; PubMed review.